Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD)

“…There is currently no gold standard available on how to best assess hallucinations (Miyasaki et al, 2006). Composite neuropsychiatric assessment scales with a hallucination section rely on informants' information and most do not take the phenomenology into account (Reisberg et al, 1987;Cummings et al, 1994;Allen et al, 1996). We identified in a pubmed search four interviews to assess visual hallucinations (Lowe, 1973;Santhouse et al, 2000;Ondo et al, 2002;Menon, 2005).…”

Section: Introductionmentioning

confidence: 99%

A semi‐structured interview to assess visual hallucinations in older people

Mosimann

Collerton

Dudley

et al. 2008

Int J Geriat Psychiatry

102

View full text Add to dashboard Cite

show abstract

“…These include: cognition: Mini-Mental State Examination (MMSE) [12] and ADAS-Cog [13] ; non-cognitive symptoms: Mini-MOUSEPAD [14] , and carer stress: General Health Questionnaire (GHQ-28) [15] .…”

Section: Methodsmentioning

confidence: 99%

Treatment of a Whole Population Sample of Alzheimer’s Disease with Donepezil over a 4-Year Period: Lessons Learned

Lyle

Grizzell²,

Willmott³

et al. 2008

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background: In the UK it is recommended that acetylcholinesterase inhibitors be restricted to patients with moderate Alzheimer’s disease, and progress monitored within specialist clinics. Objective: To describe a cohort of patients with Alzheimer’s disease from a whole city population treated with donepezil, and to analyse outcomes over 4 years. Methods: Historical cohort design: 88 patients recruited 1997–1998, assessed at baseline with 4-year follow-up, using an agreed protocol and validated measures: survival, retention in treatment, cognition, non-cognitive symptoms, weight change, carer stress. Results: 64.7% remained on treatment beyond 6 months, 57.9% beyond 1 year and 12.5% beyond 4 years. 56% remained alive at 4 years – almost twice the number predicted. Mean MMSE score amongst patients in treatment did not deteriorate over 4 years. Survival, retention in treatment, maintenance/improvement of cognition was greater with high baseline MMSE. Non-cognitive symptoms, carer stress and weight change remained low throughout. Conclusions: A minority of people with dementia from the population (88 of potential 2,000 at outset, 11 by 4 years) received treatment. Benefits for individuals were confirmed, especially for those with mild impairment. Expenditure on medication was modest in a population context. These findings question recent guidance from the National Institute for Clinical Excellence, which would restrict therapy to patients with moderate cognitive impairment.

show abstract

Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD)

Abstract: The scale may be useful as an outcome measure in drug trials, for correlating psychopathological and behavioural changes with post-mortem findings, and in epidemiological surveys.

Cited by 67 publications

References 25 publications

Family carers' responses to behavioural and psychological symptoms of dementia

Family carers' responses to behavioural and psychological symptoms of dementia

A semi‐structured interview to assess visual hallucinations in older people

Treatment of a Whole Population Sample of Alzheimer’s Disease with Donepezil over a 4-Year Period: Lessons Learned

Contact Info

Product

Resources

About